By Rob Curran


Foghorn Therapeutics shares shot higher after the biotech company said Eli Lilly will conduct clinical trials of one of Foghorn's cancer treatment candidates under the companies' joint-venture arrangement.

Foghorn said Lilly will test its FHD-909 product, an oral medicine that is a Brahma Homolog inhibitor, on patients with non-small-cell lung cancer. In genetic studies, the Brahma Homolog has been associated with certain gene mutations thought to cause cancer. Lilly will file an investigational new drug application with the U.S. Food and Drug Administration in the second quarter.

In December 2021, Foghorn entered a joint venture with Lilly to develop oncology medicines. The deal included a 50/50 split on revenue from the co-development and commercialization of products from Foghorn's Brahma Homolog inhibitor oncology program and an additional undisclosed oncology target.

Foghorn shares rose 12% to $3.50.


Write to Rob Curran at rob.curran@wsj.com


(END) Dow Jones Newswires

02-08-24 0825ET